CorMedix Inc. (CRMD) Aandelenanalyse

Bedrijfsoverzicht

CorMedix Inc. is a biopharmaceutical entity dedicated to the development and commercialization of therapeutic products aimed at treating life-threatening diseases and conditions within the United States market. The company operates within the healthcare sector, specifically classified under the biotechnology industry, which implies a focus on research-intensive innovation and high-risk, high-reward product pipelines. With a total market capitalization of $572.32M and an annual revenue of $311.71M, CorMedix maintains a workforce consisting of 191 employees. These valuation and revenue figures suggest that the company holds a moderate position in the biotechnology landscape, balancing a significant cash reserve against a relatively lean operational footprint typical of firms in the early to mid-commercialization phases of drug development.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $311.71M, generating a net income of $162.07M and an EBITDA of $174.89M. The substantial gap between the revenue figure and the net income indicates a highly efficient cost structure where operating expenses are kept well below the gross revenue threshold. CorMedix generated free cash flow of $108.51M, which provides the management team with significant financial flexibility to fund research initiatives without relying on external equity financing or debt issuance. The gross margin stands at 92.9%, reflecting the high value-add nature of biotechnology products, while the operating margin is recorded at 53.9% and the profit margin reaches 52.3%, demonstrating robust profitability across all stages of the income statement. In terms of solvency, the company holds $148.53M in cash against total debt of $148.91M, resulting in a debt-to-equity ratio of 36.74, which indicates a balance sheet that is effectively neutral regarding leverage. The current ratio of 2.11 suggests that the company possesses more than double the liquid assets required to cover its short-term liabilities, signaling strong short-term liquidity. Furthermore, the return on equity is 66.6% and the return on assets is 21.2%, metrics that reveal management's high effectiveness in deploying capital to generate returns relative to the shareholders' equity and the total asset base.

Waarderingsbeoordeling

CorMedix trades with a trailing P/E ratio of 3.55 and a forward P/E of 9.92, implying that the market expects earnings to recover or expand significantly in the coming year to justify the higher forward multiple. The price-to-book ratio is 1.42, indicating that the market values the company at a moderate premium over its net tangible book value, likely reflecting the intangible value of its intellectual property and pipeline. Alternative valuation metrics such as the price-to-sales ratio of 1.84 and an EV/EBITDA of 3.27 suggest that the stock is priced conservatively relative to its sales volume and earnings power. The 52-week price range spans from a low of $6.13 to a high of $17.43, placing the current trading price in a position that requires calculation relative to the specific day's market data, though the range defines the recent volatility envelope. The beta value of 1.41 indicates that the stock price exhibits volatility that is significantly higher than the broader market, meaning price swings will likely be amplified during periods of market stress or rally.

Growth & Income

CorMedix experienced a revenue growth year-over-year of 312.1%, while earnings growth recorded a decline of 28.3% year-over-year. This divergence implies that while top-line sales are expanding rapidly, likely due to new product launches or market penetration, the bottom-line profitability is currently being impacted by non-recurring costs or one-time adjustments that are not yet fully reflected in the net income stream. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all earnings to reinvest into research, development, and commercialization efforts rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion without current income distribution, relying on capital appreciation potential driven by the company's pipeline progress and operational scaling.